Gestational Trophoblastic Disease Global Market Report 2024

Description

Gestational trophoblastic disease (GTD) encompasses a group of rare and abnormal conditions arising from the anomalous growth of trophoblastic cells, leading to the formation of a tumor within the uterus following conception. The treatment for GTD typically involves uterine evacuation and the ongoing monitoring of human chorionic gonadotropin (hCG) levels.

The main types of gestational trophoblastic disease include hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others. A hydatidiform mole, also referred to as a molar pregnancy, is an uncommon and abnormal pregnancy condition. Treatment options for this condition include surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy. These treatments are administered by various end-users such as hospitals, clinics, diagnostic centers, and others.

The gestational trophoblastic disease market research report is one of a series of new reports from The Business Research Company that provides gestational trophoblastic disease market statistics, including gestational trophoblastic disease industry global market size, regional shares, competitors with a gestational trophoblastic disease market share, detailed gestational trophoblastic disease market segments, market trends and opportunities, and any further data you may need to thrive in the gestational trophoblastic disease industry. This gestational trophoblastic disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gestational trophoblastic disease market size has grown strongly in recent years. It will grow from $1.96 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth observed in the historical period can be attributed to public health initiatives, an enhanced understanding of disease pathology, advancements in medical research and clinical trials, the development of targeted therapies, and a shift in treatment protocols.

The gestational trophoblastic disease market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 4.8%. The anticipated growth in the forecast period can be attributed to healthcare infrastructure development, the advancement of telemedicine and remote care, the adoption of patient-centric care approaches, regulatory approvals for novel treatments, and the progress in genomic and molecular studies. Major trends expected in the forecast period include a shift towards personalized medicine, advancements in molecular diagnostics, a focus on immunotherapies and targeted therapies, the integration of digital health technologies, and the rise of awareness and education programs.

The gestational trophoblastic disease market is anticipated to witness growth due to the increasing prevalence of abnormal pregnancies. Abnormal pregnancies, deviating from the typical course, pose health risks to both the mother and the fetus, potentially leading to gestational trophoblastic disease, especially in cases such as molar pregnancies. For instance, Gov.UK reported a 1.73% increase in reported abortions in Great Britain from 2020 to 2021, with around 25% of all pregnancies ending in abortion. This surge in abnormal pregnancies, as indicated by the rising abortion rates, is a key driver for the gestational trophoblastic disease market.

The growth of the gestational trophoblastic disease market is further fueled by the increasing prevalence of cigarette smoking. Cigarette smoking, known for its harmful effects, is linked to the development of gestational trophoblastic disease. The chemicals in tobacco smoke can damage trophoblastic cell DNA, leading to abnormal growth and division and the onset of gestational trophoblastic disease. For example, Statistics Canada reported a notable 45.2% increase in cigarette production in Canada from August 2021 to August 2022. The concurrent rise in cigarette consumption reinforces the association between smoking and gestational trophoblastic disease, contributing to market growth.

The gestational trophoblastic disease market faces challenges due to low awareness and diagnosis rates. Limited knowledge among healthcare professionals and individuals may result in delayed or missed diagnoses of gestational trophoblastic disease, impacting timely intervention and patient outcomes. The American Society of Clinical Oncology reported an annual incidence of 110 to 120 cases per 100,000 pregnancies for gestational trophoblastic disease, emphasizing the need for increased awareness. The low awareness and diagnosis rates present a significant hurdle to the gestational trophoblastic disease market's growth.

Major companies operating in the gestational trophoblastic disease market are introducing updated guidelines to enhance services. The Health Service Executive National Cancer Control Programme in Ireland launched an updated gestational trophoblastic disease guideline, aiming to provide comprehensive insights into diagnostic and management strategies. By reducing practice variation and improving the quality of care, these guidelines contribute to better outcomes for gestational trophoblastic disease patients.

Companies in the gestational trophoblastic disease market are innovating treatments, such as reproductive tissue preservation solutions, to offer reliable services. Reproductive tissue preservation solutions, preserving the viability of reproductive tissue, provide flexibility and control over family-building choices. Inception Fertility introduced HavenCryo, a long-term reproductive tissue and cryopreservation storage solution, allowing indefinite storage of eggs, sperm, and embryos. This solution proves beneficial for individuals diagnosed with gestational trophoblastic disease who need fertility preservation before undergoing treatments that may impact fertility.

Major companies operating in the gestational trophoblastic disease market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Mylan N.V, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Perrigo Company plc, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., Wockhardt Ltd., Natco Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Arog Pharmaceuticals Inc., Advenchen Laboratories LLC., Mendus AB, AB Science S.A.

Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2022, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the gestational trophoblastic disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The gestational trophoblastic disease market consists of revenues earned by entities by providing services such as gynecology services, oncology services, and surgical services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational trophoblastic disease market also includes sales of medications, diagnostic tools, laboratory tests, methotrexate, etoposide, cyclophosphamide, and vincristine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gestational Trophoblastic Disease Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gestational trophoblastic disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gestational trophoblastic disease? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gestational trophoblastic disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Type: Hydatidiform Mole; Choriocarcinoma; Placental-Site Trophoblastic Tumor; Epithelioid Trophoblastic Tumor; Other Types
2) By Treatment: Surgery; Chemotherapy; Suction Dilation And Curettage (D&C); Radiation Therapy
3) By End User: Hospital And Clinics; Diagnostic Centers; Other End Users
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; AbbVie Inc.; Bayer AG; Novartis AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r13484

1. Executive Summary

2. Gestational Trophoblastic Disease Market Characteristics

3. Gestational Trophoblastic Disease Market Trends And Strategies

4. Gestational Trophoblastic Disease Market - Macro Economic Scenario

4.1. Impact Of High Inflation On The Market
4.2. Ukraine-Russia War Impact On The Market
4.3. COVID-19 Impact On The Market

5. Global Gestational Trophoblastic Disease Market Size and Growth

5.1. Global Gestational Trophoblastic Disease Market Drivers and Restraints
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints Of The Market
5.2. Global Gestational Trophoblastic Disease Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
5.3. Global Gestational Trophoblastic Disease Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gestational Trophoblastic Disease Market Segmentation

6.1. Global Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hydatidiform Mole
Choriocarcinoma
Placental-Site Trophoblastic Tumor
Epithelioid Trophoblastic Tumor
Other Types
6.2. Global Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Surgery
Chemotherapy
Suction Dilation And Curettage (D&C)
Radiation Therapy
6.3. Global Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
Hospital And Clinics
Diagnostic Centers
Other End Users

7. Gestational Trophoblastic Disease Market Regional And Country Analysis

7.1. Global Gestational Trophoblastic Disease Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Gestational Trophoblastic Disease Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gestational Trophoblastic Disease Market

8.1. Asia-Pacific Gestational Trophoblastic Disease Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gestational Trophoblastic Disease Market

9.1. China Gestational Trophoblastic Disease Market Overview
9.2. China Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gestational Trophoblastic Disease Market

10.1. India Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gestational Trophoblastic Disease Market

11.1. Japan Gestational Trophoblastic Disease Market Overview
11.2. Japan Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gestational Trophoblastic Disease Market

12.1. Australia Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gestational Trophoblastic Disease Market

13.1. Indonesia Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gestational Trophoblastic Disease Market

14.1. South Korea Gestational Trophoblastic Disease Market Overview
14.2. South Korea Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gestational Trophoblastic Disease Market

15.1. Western Europe Gestational Trophoblastic Disease Market Overview
15.2. Western Europe Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gestational Trophoblastic Disease Market

16.1. UK Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gestational Trophoblastic Disease Market

17.1. Germany Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gestational Trophoblastic Disease Market

18.5. France Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.6. France Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.7. France Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gestational Trophoblastic Disease Market

19.9. Italy Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.10. Italy Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.11. Italy Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gestational Trophoblastic Disease Market

20.13. Spain Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.14. Spain Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.15. Spain Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gestational Trophoblastic Disease Market

21.1. Eastern Europe Gestational Trophoblastic Disease Market Overview
21.2. Eastern Europe Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gestational Trophoblastic Disease Market

22.1. Russia Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gestational Trophoblastic Disease Market

23.1. North America Gestational Trophoblastic Disease Market Overview
23.2. North America Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gestational Trophoblastic Disease Market

24.1. USA Gestational Trophoblastic Disease Market Overview
24.2. USA Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gestational Trophoblastic Disease Market

25.1. Canada Gestational Trophoblastic Disease Market Overview
25.2. Canada Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gestational Trophoblastic Disease Market

26.1. South America Gestational Trophoblastic Disease Market Overview
26.2. South America Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gestational Trophoblastic Disease Market

27.1. Brazil Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gestational Trophoblastic Disease Market

28.1. Middle East Gestational Trophoblastic Disease Market Overview
28.2. Middle East Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gestational Trophoblastic Disease Market

29.1. Africa Gestational Trophoblastic Disease Market Overview
29.2. Africa Gestational Trophoblastic Disease Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Gestational Trophoblastic Disease Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Gestational Trophoblastic Disease Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gestational Trophoblastic Disease Market Competitive Landscape And Company Profiles

30.1. Gestational Trophoblastic Disease Market Competitive Landscape
30.2. Gestational Trophoblastic Disease Market Company Profiles
- 30.2.1. Pfizer Inc.
  - 30.2.1.1. Overview
  - 30.2.1.2. Products and Services
  - 30.2.1.3. Strategy
  - 30.2.1.4. Financial Performance
- 30.2.2. F. Hoffmann-La Roche AG
  - 30.2.2.1. Overview
  - 30.2.2.2. Products and Services
  - 30.2.2.3. Strategy
  - 30.2.2.4. Financial Performance
- 30.2.3. AbbVie Inc.
  - 30.2.3.1. Overview
  - 30.2.3.2. Products and Services
  - 30.2.3.3. Strategy
  - 30.2.3.4. Financial Performance
- 30.2.4. Bayer AG
  - 30.2.4.1. Overview
  - 30.2.4.2. Products and Services
  - 30.2.4.3. Strategy
  - 30.2.4.4. Financial Performance
- 30.2.5. Novartis AG
  - 30.2.5.1. Overview
  - 30.2.5.2. Products and Services
  - 30.2.5.3. Strategy
  - 30.2.5.4. Financial Performance

31. Gestational Trophoblastic Disease Market Other Major And Innovative Companies

31.1. Merck And Co. Inc.
31.2. Sun Pharmaceutical Industries Ltd.
31.3. GSK plc
31.4. Bristol-Myers Squibb Company
31.5. Sanofi S.A.
31.6. AstraZeneca plc
31.7. Eli Lilly and Company
31.8. Mylan N.V
31.9. Daiichi Sankyo Co. Ltd.
31.10. Eisai Co. Ltd.
31.11. Perrigo Company plc
31.12. Jiangsu Hengrui Medicine Co. Ltd.
31.13. Exelixis Inc.
31.14. Wockhardt Ltd.
31.15. Natco Pharma Ltd.

32. Global Gestational Trophoblastic Disease Market Competitive Benchmarking

33. Global Gestational Trophoblastic Disease Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gestational Trophoblastic Disease Market

35. Gestational Trophoblastic Disease Market Future Outlook and Potential Analysis

35.1 Gestational Trophoblastic Disease Market In 2028 - Countries Offering Most New Opportunities
35.2 Gestational Trophoblastic Disease Market In 2028 - Segments Offering Most New Opportunities
35.3 Gestational Trophoblastic Disease Market In 2028 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer